BQ Blue's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer BloombergQuint's subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Prabhudas Lilladher Report
Cadila Healthcare Ltd.'s Q3 profitability was impacted by lower domestic sales and weak gross margins. Though company has initiated cost efficiency programs it will partially help to negate pricing pressure and likely competition in some key products of U.S.
Also vaccine opportunity is not material, given the diminishing market opportunity.
We remain positive on Cadila Healthcare's growth levers such as biosimilars, injectables and vaccines which will play out gradually. Delay in key abbreviated new drug application approval is key risk to our call.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
